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Abstract
Objective—To investigate antiretroviral treatment (ART) interruption in a long-term treatment
cohort in South Africa.
Methods—All adults accessing ART between 2004 and 2009 were included in this analysis.
Defaulting was defined as having stopped all ART drugs for more than 30 days. Treatment
interrupters were patients who defaulted and returned to care during the study, whereas loss to
follow-up was defined as defaulting and not returning to care. Kaplan-Meier estimates and
Possion regression models were used to analyze rates and determinants of defaulting therapy and
of treatment resumption.
Results—Overall rate of defaulting treatment was 12.8/100 person years (95% CI 11.4-14.4).
Risk factors for defaulting were male gender, high baseline CD4 count, recency of ART initiation
and time on ART. The probability of resuming therapy within 3 years of defaulting therapy was
42% (event rate=21.4/100 person-years). Factors associated with restarting treatment were female
gender, older age, and time since defaulting.
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Conclusion—Defaulting treatment need not be an irreversible event. Interventions to increase
retention in care should target men, less immunocompromised patients and patients during the first
6 months of treatment. Resumption of treatment is most likely within the first year of interrupting
therapy.
Keywords
HIV; antiretroviral; unstructured treatment interruption; loss to follow-up; Africa
Introduction
Access to antiretroviral therapy (ART) has improved substantially in resource-limited
settings in Africa, Asia and South America where 90% of people with HIV/AIDS reside.
According to World Health Organization (WHO) estimates, more than four million people
with HIV/AIDS in low and middle income countries had initiated treatment by the end of
2008.1 Despite this success, ensuring that patients remain in care over time remains one of
the major challenges in resource-limited settings. Much attention has been paid to patient
adherence2-5, loss to follow-up, and mortality in ART programs in resource-limited settings.
6
-
9
 A systematic review of 33 patient cohorts from 13 African countries reported that only
between 46 and 85% of patients remained in care at two years.8
The realization that a substantial proportion of patients reported as lost to follow-up may
have died has led to concern that there may be significant biases in program outcome reports
of survival.10 Another potential source of bias is the fact that a proportion of patients may
only transiently default, returning to care at a later stage. Such unstructured treatment
interruption has been reported to occur in around 20% of patients in industrialized settings.
11
-
14
 The proportion of patients who transiently interrupt treatment in resource-limited
settings is largely unreported.
Treatment interruptions, planned or otherwise, have been found to increase the risk of
opportunistic infection and death15-17, with viral load increase and associated CD4 decline
most pronounced in the first two months.16, 18-20 Interruptions raise similar concerns with
respect to drug resistance and increased mortality as sub-optimal adherence.11, 15, 21-23
However, few studies have addressed the issue of unstructured treatment interruptions in
resource-limited settings. The aim of this study was to investigate the frequency and risk
factors of defaulting treatment and identify factors associated with subsequent return to care
in a long-term treatment cohort in South Africa.
Methods
Study site and data collection
The study was based in a peri-urban township in the greater area of Cape Town, with a
population of approximately 15,000 people and an estimated adult HIV prevalence of 23%
in 2005.24 The community is served by a single public-sector primary care clinic which
provides ART free of charge.
ART provision began in 2004. From 2005 to 2009 ART services were partly provided
according to the Antiretroviral Treatment Protocol of the Western Cape and partly through a
study funded by the National Institutes of Health (NIH). Patients enrolled in the NIH-funded
study could access ART with a CD4 count below 350 cells/μl or WHO stage 3 disease as
compared to 200 cells/μl or WHO stage 4 disease in the provincial program. The NIH-
funded study completed enrollment in 2007 after which all patients were treated in the
provincial ART program.
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Initial evaluation for ART eligibility included medical history, physical examination and
CD4 cell count. A follow-up appointment was scheduled one to two weeks later when the
laboratory results were reviewed and ART eligibility was determined. Patients eligible for
ART underwent three adherence counseling sessions before starting treatment.
The initial follow-up schedule for those starting ART included one visit two weeks after
ART initiation, followed by monthly visits until month three. Patients who were stable on
ART and did not experience any adherence problems were thereafter seen every three
months. Three attempts were made to contact patients who had missed appointments.
All patients aged ≥15 years accessing ART in the primary health care clinic between 01
March 2004 and 31 December 2009 were included in the analysis.
Sociodemographic and clinical data at baseline and laboratory data were collected
prospectively using a standardized data form. All laboratory tests were performed by the
National Health Laboratory Services in Cape Town.
Definitions
Patients defaulting treatment were defined as those who had not presented at the pharmacy
for ART refills for more than 30 days. This category included patients who subsequently
returned to care and restarted ART (treatment interrupters) and patients who had not
returned to care at the time of censoring (loss to follow-up) (figure 1).
Treatment interruption was defined as a patient-initiated episode of more than 30 days of
stopping ART (same definition as defaulting) but who subsequently resumed treatment
(figure 1).
Patients lost to follow-up were those who stopped ART for more than 30 days and had not
returned to care at the time of censoring (figure 1).
Study design
In-programme data on death, transfers outs and loss to follow-up were collected
prospectively. Death on ART was defined as any death within three months of drug refill. If
the exact date of death was not recorded it was estimated to be the 15th of the month
following the last clinic appointment.
Patients who had stopped ART for more than 30 days and resumed therapy were identified
using the pharmacy dispensing data. The electronic pharmacy dispensing system records
each time medication is dispensed to a patient. Treatment interruption was verified through
folder reviews.
The first endpoint was the time from ART initiation to the first time at which all drugs were
stopped for a period of at least 30 days (default). Follow-up of patients on continuous
therapy was censored at the date of death, date of transfer, or study end (31 December
2009).
The second endpoint was treatment resumption, defined as the time from defaulting
treatment for the first time to the time of restarting ART. Follow-up of patients for whom
therapy was not resumed was censored at the date of death, date of transfer, date of
migration, or study end. For a proportion of these patients (48%) vital status, date of death,
date of transfer and date of migration was determined by home visits.
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Statistical analysis
All analyses were carried out using Stata version 10.0 (Stata Corp. LP, College Station, TX,
United States of America). Frequency tables were produced for all categorical baseline
characteristics. For continuous baseline characteristics the median and interquartile ranges
were reported. Standard survival analysis methods, including Kaplan-Meier estimates and
Poisson regression models were used to analyze the rate and determinants of defaulting
therapy and of treatment resumption after defaulting treatment for the first time. The
proportional hazards assumption for potential interaction between each variable and time
was tested using the likelihood ratio test. A univariate Poisson regression model was used to
determine risk for time-to-event outcomes for each exposure variable. Multivariate models
were built through backwards elimination. Sensitivity analyses were conducted excluding
individuals with unascertained vital status. All reported p values are exact and 2-tailed, and
for each analysis p<0.05 was considered significant.
Ethical approval
The study was approved by the University of Cape Town Ethics Committee and the London
School of Hygiene and Tropical Medicine Ethics Committee. Written informed consent was
obtained from all patients at enrolment.
Results
Patient characteristics
A total of 1154 patients were included in the analysis (table 1) and the median time of
follow-up was 1.45 years (IQR: 0.48-3.24). The majority of patients were young women
(65.2%) and residents in the township (95.5%). Prior to treatment initiation the majority of
patients were in WHO clinical stage 3 (51.1%) and 4 (25.1%) and median CD4 count was
122 cells/μl (IQR: 54-190). The number of patients initiating ART per year doubled from
137 in 2004 to 279 in 2006 and declined thereafter.
A total of 291 patients defaulted treatment at least once (figure 1). Among these, 96 resumed
therapy (treatment interruption) while 195 did not resume therapy during follow-up (lost to
follow-up). Of the 96 individuals resuming therapy, 75 individuals had one episode of
treatment interruption, 19 had two and 2 had three. The median time patients failed to
receive ART was 228 days (IQR: 126-409) during the first episode of treatment default and
194 days (IQR 121-278) during the second episode. Thirty five patients who had stopped
treatment underwent re-screening that included clinical assessment, laboratory tests and
adherence counseling and yet did not resume therapy during the period of the study.
Subsequent analyses investigated first episode of treatment interruption by analyzing the
time to stopping treatment for the first time and resuming therapy thereafter (non-shaded
cells in figure 1).
Factors associated with the probability of defaulting treatment
The overall rate of treatment default for the first time was 12.8/100 person years (PYs) (95%
CI 11.4-14.4). The Kaplan-Meier estimate of the probability of defaulting treatment for at
least 30 days was 14.9% (95% CI 12.7-17.4) by 1 year, 25.6% (95% CI 22.7-28.8) by 2
years and 41.0% (95% CI 37.0-45.3) by 5 years from ART initiation (figure 2).
Factors associated with increased risk of defaulting therapy in univariate analysis were male
gender, higher baseline CD4 count, recency of ART initiation and shorter duration on ART
(table 2). Defaulting rate was highest in the first six months of ART (18.2/100 PYs, 95% CI
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14.7-22.5) but decreased thereafter and had more than halved after two years (8.8/100 PYs,
95% CI 7.0-11.0).
Gender, baseline CD4 count, time on ART, and date of initiation remained significantly
associated with defaulting in the multivariate model. Men were 1.51 (95% CI 1.18-1.93)
times more likely to default treatment compared to women, as were those patients with a
higher baseline CD4 count. The adjusted hazard of defaulting treatment increased by 1.30
(95% CI 1.17-1.44) for each calendar year. Patients on treatment for more than 2 years had a
lower hazard of 0.69 (95% CI 0.48-0.98) of defaulting compared to patients during the first
6 months of treatment. Similar results were found in a sensitivity analysis that excluded
individuals whose vital status could not be ascertained.
Factors associated with the probability of resuming therapy
A total of 291 patients defaulted treatment at least once. The overall rate of treatment
resumption after defaulting treatment for the first time was 21.4/100 PYs (95% CI
17.5-26.2) (figure 3). The Kaplan-Meier cumulative estimate of the probability of treatment
resumption was 26.7% (95% CI 21.7-32.7) in the first year, 37.1% (95% CI 31.1-43.9) in
the second year and 42.1% (95% CI 35.2-49.7%) in the third year after stopping treatment.
In univariate analysis a greater likelihood of resuming ART was associated with older age
and shorter time since defaulting (table 3); gender, residency, calendar year of defaulting
and CD4 count nearest to the time of defaulting was not associated with resuming treatment.
In multivariate analysis men were less likely to resume treatment compared to women (IRR
0.67, 95% CI 0.43-1.04, p=0.07); whereas patients >30 years old were more likely to restart
treatment (IRR 1.80, 95% CI 1.13-2.89). The likelihood of resuming treatment decreased
significantly beyond one year of defaulting treatment (IRR 0.40, 95% CI 0.25-0.63).
Of the 96 patients resuming therapy, 86 had a CD4 count measurement while receiving
therapy and before the treatment interruption; the majority of these (80) responded to ART
with an increase in CD4. Patients who resumed therapy were found to have a median CD4
count (150.5 cells/μl, IQR: 73-266) comparable to their baseline CD4 count prior to
initiating therapy (138.5 cells/μl, IQR: 73-188). The median time between the measurement
of CD4 count and resuming therapy was 13 days (IQR 0-28 days).
Excluding individuals with unascertained vital status revealed similar results with regards to
parameter estimates, but the association with male gender became non-significant (HR 0.81,
95% CI 0.52-1.26, p=0.35).
Discussion
To our knowledge, this is the first study from sub-Saharan Africa to report on unstructured
treatment interruptions in a routine programme setting. Our analysis shows that treatment
interruption is a common phenomenon. The probability of ART defaulters to resume therapy
within 3 years was 42%. Most ART cohorts report on loss to follow-up defined as not
attending the clinic for more than 3 months,8 and assume that loss to follow-up is an
irreversible event. Our study shows that patients who fulfil the widely used definition of loss
to follow-up at one time point might resume therapy later. In this cohort, the median
duration of the first treatment interruption was 7.5 months.
The median CD4 count of those resuming therapy was similar to their initial CD4 count
prior to starting treatment, which underscores the potentially negative impact of interruption
leading to a reversal in immunological recovery made while on treatment. Data from
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industrialised settings suggest that treatment interruption has detrimental effects on CD4
count, viral load suppression, and clinical progression.11, 12, 19 Programmes that report
patient attrition and the number of patients in care will not account for the potential that up
to 14% of patients in care have interrupted treatment at least once.
We were able to determine risk factors for defaulting ART and factors associated with
resuming therapy. Male gender, high baseline CD4 count, recency of ART initiation and the
first 6 months of treatment were associated with a higher risk of defaulting. Treatment
resumption was more likely in women, patients more than 30 years old and within the first
year of stopping therapy.
Our finding that men were at higher risk of defaulting treatment and less likely to resume
treatment is consistent with studies showing that HIV-infected men are less likely to access
treatment25, 26, have an increased risk for loss to follow-up in the pre-treatment period27,
present with more advanced stages of HIV disease28 and have a higher mortality risk on
ART.2, 9, 29-33 Strategies to diagnose HIV in men earlier and to link and to retain them in
care might include: i) extending clinic hours into evenings and weekends, ii) training male
health care staff and counsellors, iii) offering additional adherence sessions to men and iv)
initiating male support groups.
Individuals initiating treatment in more recent years were more likely to default, suggesting
that programmatic factors might influence retention in care. A study including data from 15
treatment cohorts from Africa, Asia and South America showed that early patient losses
were increasingly common when programs were scaled up.6 Increasing cohort size in an
environment of scarce human resources for health has been suggested to influence both the
scale-up capacity and the long-term retention in ART programs.34 In the study clinic
resources and staffing were further reduced when enrolment for the NIH-funded study
finished in 2007. In contrast, year of defaulting was not associated with resumption of
treatment, suggesting that patient tracing was less influenced by cohort size (although this
would vary according to tracing procedures).
Treatment defaulting was more likely in patients with less advanced immunodeficiency at
baseline. This may be explained by the fact that individuals who default treatment and stay
alive do so because they feel better on treatment, a phenomenon that has been reported by
other studies.35 This finding is particularly important in view of the 2009 WHO guidelines
recommending ART initiation at CD4 counts below 350 cells/ μl36 and when considering
initiation of ART regardless of CD4 count as proposed in the ‘test and treat’ strategy.37
Initiating ART at the time of HIV diagnosis will result in increased numbers of relatively
immunocompetent individuals on ART who may have a higher risk of defaulting treatment.
Specific interventions aimed at these individuals need to be developed to ensure optimal
retention in care.
This study has several limitations. First, ascertainment of vital status for treatment defaulters
was incomplete, which may have led to a misclassification of deaths as defaulters. However,
sensitivity analysis excluding individuals with unascertained vital status did not influence
our overall findings. Second, resumption of therapy was not ascertained in patients who
moved to other communities, possibly resulting in underestimation of treatment resumption.
Third, the clinical and immunological consequences of treatment interruption were not
analysed due to lack of laboratory data, in particular the lack of capacity to perform routine
viral load, and the small number of individuals resuming therapy. However it has been
shown in industrialised settings that treatment interruption impacts negatively on CD4
count, viral load suppression and clinical progression.11, 12, 19
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We consider that the main finding of this study that a considerable proportion of treatment
defaulters return to care is likely to be generalisable to similar settings. Nevertheless, risk
factors for defaulting and resuming therapy might differ with regards to eligibility criteria
and resources available for patient tracing.
A strength of this study is that the relatively large sample size and follow up time. This
allows for an assessment of risk factors for defaulting and treatment interruption that in turn
allows for several proposals to be made to limit defaulting and treatment interruption in
similar programme settings. In particular, interventions to keep patients in care should be
targeted at men, patients with higher CD4 counts and during the first 6 months of ART.
Moreover, the finding that the probability of resuming therapy was highest in the first year
following treatment defaulting suggests that efforts to bring patients back into care might be
most successful early into defaulting treatment.
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Figure 1. Flow chart of patients in care, first time defaulters and treatment interrupters
1 Defaulting treatment was defined as having stopped all ART drugs for more than 30 days.
This category included patients who subsequently returned to care and restarted ART
(treatment interrupters) and patients who had not returned to care at the time of censoring
(loss to follow-up).
2 Loss to follow-up was defined as stopping ART for more than 30 days and not returning to
care at the time of censoring.
3 Treatment interruption was defined as a patient-initiated episode of more than 30 days of
stopping ART and subsequently resuming treatment.
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Figure 2.
Kaplan Meier plot showing the probability of not defaulting antiretroviral therapy (ART)
from the time of initiating ART up to the end of the 5th year of treatment
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Figure 3.
Kaplan Meier plot showing the probability of resuming antiretroviral therapy (ART) from
the time of defaulting therapy up to 3 years after defaulting treatment
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Table 1
Baseline characteristics of patients (n=1154) who enrolled in the ART programme between 2004 and 2009
Variable N (%) Median (IQR)
Gender
Women 752 (65.2)
Men 402 (34.8)
Age (years) 31.9 (27.3; 37.5)
Residents in the study township
Yes 1102 (95.5)
No 40 (3.5)
Unknown 12 (1.0)
Transferred in from another ART
service
No 1046 (90.6)
Yes 108 (9.4)
Year of initiating ART
2004 137 (11.9)
2005 242 (21.0)
2006 279 (24.2)
2007 153 (13.3)
2008 155 (13.4)
2009 188 (16.3)
WHO clinical stage1
1 106 (9.3)
2 166 (14.5)
3 585 (51.1)
4 287 (25.1)
Baseline CD4 (cell/μl)2 122 (54; 190)
110 missing values
2114 missing values
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